SeraCare Expands Genetic Portfolio with New ACCURUN® Product

MILFORD, Mass., April 8, 2014 /PRNewswire/ -- SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of its new ACCURUN® 611 product, a robust product that demonstrates consistent performance over time. This reference material is designed to support detection of the Factor V Leiden mutation and the Factor II gene variant, as well as mutations in the Methlyenetetrahydrofolate reductase (MTHFR) gene that are associated with significant health problems.

ACCURUN 611 for Factor II, Factor V, and MTHFR

ACCURUN® 611 meets the needs of a broad range of molecular lab applications by providing heterozygous, mutant, or wild type scores for Factor II, Factor V, and MTHFR. It is ready-to-use genomic DNA manufactured from immortalized Peripheral Blood Mononuclear Cells (PBMCs) derived from human samples. Mutations were confirmed by a variety of commercial SNP genotyping assays, providing a robust challenge for all mutations in only two vials.

"ACCURUN® 611 is the first product on the market for this application that uses human-derived materials that closely resemble the target samples and provide a better monitor of the detection process," said Russell Garlick, Ph.D., Chief Scientific Officer at SeraCare. "This product is an important addition to our genetic offerings and reflects our commitment to empowering researchers with the tools they need to address today's diagnostic challenges."

SeraCare's new ACCURUN® 611 product is available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit www.seracare.com.

About SeraCare Life Sciences, Inc.

SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, KPL™ antibodies and immunoassay reagents, SeraCon™ processed plasma, specialty human blood products, and Complete BioCollections™ materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.

Company Contact:
Marsha Ann Marsh
SeraCare Life Sciences, Inc.
508.244.6400 ext. 6106
mmarsh@seracare.com
www.seracare.com

  • <<
  • >>